Business
Opus Genetics Launches Gene Therapy Clinical Trial for MERTK-related Retinitis Pigmentosa
The trial is funded through Abu Dhabi’s Healthcare Research and Innovation FundClinical development activities will commence at Cleveland Clinic Abu Dhabi in 2026MERTK-related retinitis pigmentosa affects an estimated 60,000 patients worldwide RESEARCH TRIANGLE PARK, N.C., Jan. 27, 2026 (GLOBE NEWSWIRE) -- Opus Genetics, Inc. (Nasdaq: IRD), a clinical-stage biopharmaceutical company developing gene therapies to restore vision and prevent blindness in patients with inherited retinal diseases (IRD
About this update from Opus Genetics, Inc.
[{"type":"image","alt":"Opus Genetics, Inc.","displaySize":"","headline":null,"caption":"Opus Genetics, Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":129,"url":"https://media.zenfs.com/en/globenewswire.com/df50c41a115dee0675cbe3b477dc2db0"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/8o4zybgloi24hra3hobbTg--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTE4MTtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/df50c41a115dee0675cbe3b477dc2db0","width":300,"height":129}},"lazy":false},{"type":"list","items":[{"val":[{"type":"text","content":"The trial is funded through Abu Dhabi’s Healthcare Research and Innovation Fund","length":79,"tagName":"p"}]},{"val":[{"type":"text","content":"Clinical development activities will commence at Cleveland Clinic Abu Dhabi in 2026","length":83,"tagName":"p"}]},{"val":[{"type":"text","content":"MERTK-related retinitis pigmentosa affects an estimated 60,000 patients worldwide","length":81,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":243,"olType":false},{"type":"text","content":"RESEARCH TRIANGLE PARK, N.C., Jan. 27, 2026 (GLOBE NEWSWIRE) -- Opus Genetics, Inc. (Nasdaq: IRD), a clinical-stage biopharmaceutical company developing gene therapies to restore vision and prevent blindness in patients with inherited retinal diseases (IRDs), today announced the launch and funding of its clinical trial evaluating a gene therapy for MERTK-related retinitis pigmentosa (RP), a rare inherited eye disease that causes progressive vision loss and eventual blindness.","length":480,"tagName":"p"},{"type":"text","content":"The study is being launched in Abu Dhabi, the capital of the United Arab Emirates in collaboration with the Department of Health – Abu Dhabi (DoH), Cleveland Clinic Abu Dhabi, the Innovative Research Oversight and Support (IROS) division of the M42 group, and the Authority of Social Contribution – Ma’an. Cleveland Clinic Abu Dhabi will serve as the clinical site, equipped with advanced diagnostic imaging, surgical expertise and specialized retinal disease clinics.","length":468,"tagName":"p"},{"type":"text","content":"The clinical trial will evaluate the safety and efficacy of OPGx-MERTK, an investigational adeno-associated virus (AAV)-based gene therapy developed by Opus Genetics. The therapy is designed to deliver a functional copy of the MERTK gene to retinal cell...